|
Natural, soy-based substance might help fight MS, Jefferson neuroscientists find
December 13, 2006(PHILADELPHIA) - A natural substance made from soy appears to have amazing restorative powers when given to animals with a multiple sclerosis (MS)-like disease.
Using an animal model of MS, neurologists at Jefferson Medical College found that giving doses of a substance called Bowmann-Birk Inhibitor Concentrate (BBIC) dramatically improved the animals' ability to move and walk. The scientists, led by A. M. Rostami, M.D., Ph.D., professor and chair of the Department of Neurology at Jefferson Medical College of Thomas Jefferson University and the Jefferson Hospital for Neuroscience in Philadelphia, say the treatment's effects may be useful in conjunction with more mainstream therapies such as beta-interferon in helping patients with MS. They report their findings December 12, 2006 in the journal Multiple Sclerosis.
MS, one of the most common neurological diseases affecting young adults, is thought to be an autoimmune disease (in which the body attacks its own tissue) affecting the central nervous system (CNS). In MS, the myelin coating of nerve fibers becomes inflamed and scarred. As a result, "messages" cannot be sent through the nervous system.
Dr. Rostami, who is also director of the Neuroimmunology Laboratory in the Department of Neurology at Jefferson Medical College, and his group used an animal model of experimental autoimmune encephalomyelitis (EAE), which mimics MS, to investigate BBIC's potential immune system-suppressing properties. BBIC inhibits proteases, enzymes that play important roles in the inflammation and demyelination processes that are at the heart of MS. It has been used for other conditions, notably precancerous conditions in the mouth.
He and his co-workers compared two groups of animals with EAE. One group received BBIC, while the other received only an inert substance. "Animals that received BBIC were able to walk while those that didn't get the drug were not," he says. He notes that the animals aren't cured but can walk with some limp or weakness. "The results are promising because this is a safe, natural compound from soybean and is given orally."
Further analysis revealed that the central nervous systems of animals that received BBIC showed "significantly less inflammation and demyelination" than those that didn't receive the therapy. "It's the first time that BBIC has been used in an EAE model and has shown significant disease suppression, and we hope it can eventually be used in humans," says Dr. Rostami. His group's next step is to design clinical trials in humans.
The scientists are not sure how BBIC works in multiple sclerosis, but they theorize that it suppresses the immune response to some extent, in addition to inhibiting proteases. Dr. Rostami sees BBIC as being used as a single therapy or in conjunction with other drugs in treating MS. He notes that because current therapies for MS involve injecting drugs such as interferon and copaxane, one goal is to develop an oral agent. BBIC could be given by pill daily.
Over 400,000 Americans acknowledge having MS, though nearly one million Americans may be living with the disease. Symptoms can include fatigue, loss of coordination, muscle weakness, numbness, inability to walk or use hands and arms, pain, vision problems, slurred speech and bladder/bowel dysfunction.
Thomas Jefferson University
Dr. Rostami, who is also director of the Neuroimmunology Laboratory in the Department of Neurology at Jefferson Medical College, and his group used an animal model of experimental autoimmune encephalomyelitis (EAE), which mimics MS, to investigate BBIC's potential immune system-suppressing properties. BBIC inhibits proteases, enzymes that play important roles in the inflammation and demyelination processes that are at the heart of MS. It has been used for other conditions, notably precancerous conditions in the mouth.
He and his co-workers compared two groups of animals with EAE. One group received BBIC, while the other received only an inert substance. "Animals that received BBIC were able to walk while those that didn't get the drug were not," he says. He notes that the animals aren't cured but can walk with some limp or weakness. "The results are promising because this is a safe, natural compound from soybean and is given orally."
Further analysis revealed that the central nervous systems of animals that received BBIC showed "significantly less inflammation and demyelination" than those that didn't receive the therapy. "It's the first time that BBIC has been used in an EAE model and has shown significant disease suppression, and we hope it can eventually be used in humans," says Dr. Rostami. His group's next step is to design clinical trials in humans.
The scientists are not sure how BBIC works in multiple sclerosis, but they theorize that it suppresses the immune response to some extent, in addition to inhibiting proteases. Dr. Rostami sees BBIC as being used as a single therapy or in conjunction with other drugs in treating MS. He notes that because current therapies for MS involve injecting drugs such as interferon and copaxane, one goal is to develop an oral agent. BBIC could be given by pill daily.
Over 400,000 Americans acknowledge having MS, though nearly one million Americans may be living with the disease. Symptoms can include fatigue, loss of coordination, muscle weakness, numbness, inability to walk or use hands and arms, pain, vision problems, slurred speech and bladder/bowel dysfunction.
Thomas Jefferson University
Neuroscientists News and Current Neuroscientists Events RSSScientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.
Statins have unexpected effect on pool of powerful brain cells
Cholesterol-lowering drugs known as statins have a profound effect on an elite group of cells important to brain health as we age, scientists at the University of Rochester Medical Center have found. The new findings shed light on a long-debated potential role for statins in the area of dementia.
Scientists set out to measure how we perceive naturalness
Natural products are highly valued by consumers yet their properties have been difficult to reproduce fully in synthetic materials, placing a drain on our limited natural resources. Until now ...
NYU, Rutgers study shows how using mental strategies can alter the brain's reward circuitry
The cognitive strategies humans use to regulate emotions can determine both neurological and physiological responses to potential rewards, a team of New York University and Rutgers University neuroscientists has discovered.
Scientists find how neural activity spurs blood flow in the brain
New research from Harvard University neuroscientists has pinpointed exactly how neural activity boosts blood flow to the brain. The finding has important implications for our understanding of common brain imaging techniques such as fMRI, which uses blood flow in the brain as a proxy for neural activity.
Study of marine snail leads to new insights into long-term memory
UCLA cellular neuroscientists are providing new insights into the mechanisms that underlie long-term memory - research with the potential to treat long-term memory disorders.
Neuroscientists Show Insulin Receptor Signaling Regulates Structure and Function of Brain Circuits
A team of neuroscientists at Cold Spring Harbor Laboratory (CSHL) has demonstrated for the first time in living animals that insulin receptors in the brain can initiate signaling that regulates both the structure and function of neural circuits.
Neuroscientists Uncover Possible Link Between Different Forms of Epilepsy
Carnegie Mellon University neuroscientists have identified what may be the first known common denominator underlying inherited and sporadic epilepsy - a disruption in an ion channel called the BK channel.
QBI neuroscientists make Alzheimer's disease advance
Queensland Brain Institute (QBI) neuroscientists at UQ have discovered a new way to reduce neuronal loss in the brain of a person with Alzheimer's disease.
Human stem cells show promise against fatal children's diseases
Scientists have used human stem cells to dramatically improve the condition of mice with a neurological condition similar to a set of diseases in children that are invariably fatal, according to an article in the June issue of the journal Cell Stem Cell.
More Neuroscientists News Articles
 | Proust Was a Neuroscientist by Jonah Lehrer |
 | A Primate's Memoir: A Neuroscientist's Unconventional Life Among the Baboons by Robert M. Sapolsky |
 | The Spiritual Brain: A Neuroscientist's Case for the Existence of the Soul by Mario Beauregard, Denyse O'leary |
 | Neuroscience and the Law |
 | Neuroanatomy for the Neuroscientist by Stanley Jacobson, Elliott M. Marcus |
 | Lifting Depression: A Neuroscientist's Hands-On Approach to Activating Your Brain's Healing Power by Kelly Lambert |
 | Signal Processing for Neuroscientists: An Introduction to the Analysis of Physiological Signals by Wim van Drongelen |
 | Conversations on Consciousness: What the Best Minds Think about the Brain, Free Will, and What It Means to Be Human by Susan Blackmore |
 | What Makes Us Think?: A Neuroscientist and a Philosopher Argue about Ethics, Human Nature, and the Brain by Jean-Pierre Changeux, Paul Ricoeur |
 | Iconoclast: A Neuroscientist Reveals How to Think Differently by Gregory, Ph.D. Berns |
| © 2008 BrightSurf.com |